Stentys Self-Apposing® Technology and Latest Clinical Results in the Spotlight at EuroPCR

Published: May 10, 2012

PRINCETON, N.J., and PARIS, May 10, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent approved to treat Acute Myocardial Infarction (AMI) and bifurcations, has announced the agenda of next week’s EuroPCR congress, where its Self-Apposing stent technology will be showcased.

Tuesday, May 15, at 17:00in Room 243:“How Should I Treat: Solutions for Tough Cases in STEMI”will be chaired by Prof. William Wijns, M.D., and Prof. Christian Spaulding, M.D.

Wednesday, May 16, at 16:50 in Theatre Havane: “Tools and Techniques: Latest Generation Self-Expanding Stents in STEMI and Bifurcations”will be chaired by Prof. Patrick Serruys, M.D., and Prof. Eberhard Grube, M.D., and will showcase two educational ‘live’ cases.

Friday, May 18, at 09:00in Room 251: the results of the APPOSITION III study on 1,000 STEMI patients at 30 days will be presented byDr. Giovanni Amoroso, M.D.

The STENTYS Self-Apposing® Stent solves the stent-sizing dilemma that cardiologists are faced with when treating patients with complex anatomies. It “fits snugly” into the contour of a blood vessel, and its shape and diameter can adapt when the vessel dilates, eliminating malapposition and subsequent major complications seen with all other conventional stents.


Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI) and bifurcation lesions. Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its Self-Apposing stent adapts to the anatomic changes of arteries in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

Back to news